New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 15, 2014
05:47 EDTLLYEli Lilly announces results from five datasets from Alzheimer's disease study
Eli Lilly announced results from an analyses of five datasets evaluating the relationship between cognitive and functional impairment in patients with mild Alzheimer's disease in the natural course of the disease. Analysis findings demonstrate that cognitive deficits predict subsequent functional deficits and suggest that cognitive decline experienced by patients is followed by an observable related decline in function, consistent with previously proposed hypotheses. These data were presented today at the Alzheimer's Association International Conference 2014 in Copenhagen, Denmark as part of the featured research session, "Statistics in the Race against Alzheimer's Disease." Hong Liu-Seifert, Ph.D., study research advisor at Eli Lilly stated, "These data support the concept that decline in cognition is later reflected in changes in function. This suggests that with treatments that target the underlying neuropathology of disease, effects on function may take longer to observe in clinical studies. Currently available scales were not developed to assess subtle functional changes or treatment effects on these deficits in patients with early or mild Alzheimer's disease, and there is debate as to how much variability exists in these scales globally. Therefore, we support discussion of alternative ways to demonstrate clinical meaningfulness in early or mild Alzheimer's disease."
News For LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 29, 2015
10:45 EDTLLYOptions with increasing volume
Subscribe for More Information
10:43 EDTLLYEli Lilly calls active as shares at record high
Subscribe for More Information
10:09 EDTLLYHigh option volume stocks
Subscribe for More Information
08:03 EDTLLYEli Lilly and AstraZeneca enters into clinical trial collaboration
Subscribe for More Information
May 28, 2015
11:02 EDTLLYEli Lilly granted FDA orphan status for treatment of sickle cell disease
Subscribe for More Information
08:35 EDTLLYEli Lilly reports final results of Phase III trial for Alimta
Eli Lilly announced final results of the Phase III PROCLAIM trial, a randomized, Phase III superiority study of patients with locally-advanced, nonsquamous non-small cell lung cancer, which evaluated Lilly's Alimta in combination with cisplatin with concurrent radiation followed by maintenance Alimta in comparison with etoposide and cisplatin plus concurrent radiation, followed by consolidation chemotherapy of the oncologist's choice. Those treated on the pemetrexed arm achieved a median overall survival of 26.8 months as compared to 25 months for those treated on the etoposide arm. Median progression-free survival was 11.4 months on the pemetrexed arm versus 9.8 months on the etoposide arm and an overall response rate of 35.9% on the pemetrexed arm and 33% on the etoposide arm.
08:09 EDTLLYEli Lilly to present data from several trials of Cyramza for cancer
Subscribe for More Information
May 27, 2015
08:32 EDTLLYEli Lilly's Humalog KwikPen approved by FDA
Subscribe for More Information
May 22, 2015
10:52 EDTLLYJPMorgan says Actavis shares cheap compared to peers
Subscribe for More Information
May 21, 2015
07:37 EDTLLYPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use